Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
ETON 11.06.2024
Drug:1-alkindi ALKINDI SPRINKLE®
Drug:2-golike PKU GOLIKE®
Drug:3-carglumicacid Carglumic Acid
Drug:4-betaine Betaine Anhydrous
Drug:5-nitisinone Nitisinone
Drug:6-et400 ET-400
Drug:7-et600 ET-600
Drug:8-hydrocortisone ZENEO® hydrocortisone autoinjector
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Eton Pharmaceuticals Q3 2024 Financial Results Conference Call
About Gravity Analytica
Recent News
- 01.03.2025 - Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
- 12.20.2024 - Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
- 12.17.2024 - Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Recent Filings
| Dial in (Audio Only) | Toll-free: 888-596-4144 | |
| Non-toll free: 646-968-2525 | ||
| Access Code: 1144771 | ||
| Webcast: | Click Here | |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to:investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website athttps://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-
Investor Relations:
Source:
Source: Eton Pharmaceuticals